| Description: |
Sanjay Sethi,1 Emily S Wan,2,3 Vickram Tejwani,4,5 Claudia Lamprey,6 Kavita Aggarwal,6 Amy Dixon,6 Yi Pan,7 Trishul Siddharthan8 1Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USA; 2Channing Division of Network Medicine, Brigham and Young Women’s Hospital, Boston, MA, USA; 3VA Boston Healthcare System, Jamaica Plain, MA, USA; 4Department of Pulmonary Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA; 5Department of Systems Biology and Genome Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; 6Verona Pharma plc, Raleigh, NC, USA; 7Stratevi, Boston, MA, USA; 8Division of Pulmonary, Critical Care, and Sleep Medicine, University of Miami Miller School of Medicine, Miami, FL, USACorrespondence: Trishul Siddharthan, Division of Pulmonary, Critical Care and Sleep Medicine, University of Miami Miller School of Medicine, 1951 NW 7th Ave, Suite 2308, Miami, FL, 33136, USA, Tel +1 305-243-6388, Email tsiddhar@miami.eduBackground: Chronic obstructive pulmonary disease (COPD) is a progressive disease that has a great impact on healthcare resource utilization (HRU). Large-scale real-world evidence studies evaluating the clinical and economic impact of current maintenance inhaler therapies are scarce.Objective: To assess annual exacerbation rate and COPD-related HRU in patients with COPD before and after initiation of an inhaled treatment regimen.Methods: The Optum Clinformatics® Data Mart database was used to identify inpatient, outpatient, and pharmacy claims from patients aged ≥ 40 years with COPD in the United States from January 2016 to June 2023. The index date was the date of the first prescription claim for a new inhaled maintenance therapy after a 12-month maintenance treatment-free baseline period. The primary outcome was the proportion of patients with ≥ 1 moderate/severe exacerbation within 12 months post-index. The average number of moderate/severe exacerbations per patient and the ... |